Showing 2831-2840 of 5685 results for "".
- Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible Hydra-PEG Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-on-several-lenses/2476297/Bausch + Lomb announced it has received 510(k) clearance for use of the Tangible Hydra-PEG custom contact lens coating technology with some of its leading Boston gas permeable (GP) materials, the Boston XO, Boston XO2, Boston EO, and Boston ES lenses, including th
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- Silgan to Debut Iridya Preservative-Free Multi-dose Eye Dropperhttps://modernod.com/news/silgan-to-debut-iridya-preservative-free-multi-dose-eye-dropper/2476322/Silgan Dispensing will highlight its newest ophthalmic dispensing solution, Iridya, at this year’s Pharmapack, Europe’s dedicated pharmaceutical packaging and drug delivery event. Iridya is a next-generation, preservative-free multi-dose, eye dropper that improves on existing technology by
- Zeiss Develops Multifunctional Smart Glasshttps://modernod.com/news/zeiss-develops-multifunctional-smart-glass/2476327/For the first time, a technology developed by Zeiss has made it possible to utilize transparent glass or plastic in a whole range of different ways, according to a company news release. The see-through surfaces with integrated, invisible microstructured optics permit a range of different applicat
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Study: Scleral Lenses Coated with Tangible Hydra-PEG Improve Dry Eye Symptoms, Comforthttps://modernod.com/news/study-scleral-lenses-coated-with-tangible-hydra-peg-improve-dry-eye-symptoms-comfort/2476344/Tangible Science announced that a
- Statement From FDA Leadership On a Record Year for Device Innovationhttps://modernod.com/news/statement-from-fda-leadership-on-a-record-year-for-device-innovation/2479598/FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director for the Center for Devices and Radiological Health, released the following statement addressing a record year for device innovation: “The FDA’s focus on both safety and innovation stems from our historic mission
- MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF for Ophthalmic Diseaseshttps://modernod.com/news/manf-therapeutics-receives-notice-of-allowance-from-us-patent-trademark-office-covering-the-use-of-manf-or-cdnf-for-ophthalmic-diseases/2476184/MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The